Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

New Leukemia Drug Gets FDA Nod

WebMD Health News
Reviewed by Louise Chang, MD

Sept. 7, 2012 -- The FDA has approved Pfizer's Bosulif for the treatment of chronic myelogenous leukemia (CML) for people who do not respond to or who cannot tolerate other treatments.

CML is a relatively rare disease. It strikes about 5,400 people a year. Most people have a rare mutation, dubbed the Philadelphia mutation, which causes the bone marrow to make too much tyrosine kinase enzyme. Bosulif inhibits this enzyme.

Other drugs approved for CML -- Gleevec and Tasigna from Novartis and Sprycel from Bristol-Myers Squibb -- inhibit tyrosine kinase in other ways.

"With the approval of tyrosine kinase inhibitors, we are seeing improvements in the treatment of CML based on a better understanding of the molecular basis of the disease," said Richard Pazdur, MD, director of the FDA's office of hematology and oncology products, said in a news release.

In clinical trials, 55% of CML patients previously treated with Gleevec or other drugs had a return to normal blood counts with no sign of leukemia within the first 48 weeks of treatment with Bosulif.

The most common side effects of Bosulif are diarrhea, nausea, low blood platelet levels, vomiting, abdominal pain, rash, anemia, fever, and fatigue.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health